69872-37-3

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-4'-methylacetophenone is utilized as a key intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its chemical structure allows for the creation of a wide range of medicinal compounds, enhancing the industry's capacity to address various health conditions.
Used in Agrochemical Production:
In the agrochemical sector, 2-Amino-4'-methylacetophenone is employed as a fundamental building block for the production of various agrochemicals. Its role in this industry is crucial for the development of effective pesticides, herbicides, and other agricultural chemicals that protect crops and improve overall agricultural productivity.
Used in Pigment Industry:
2-Amino-4'-methylacetophenone also finds application in the pigment industry, where it is used in the synthesis of different types of pigments. Its contribution to the creation of pigments is significant for various applications, including the coloring of plastics, textiles, inks, and coatings, ensuring a diverse color palette for industrial use.

Upstream product

• 619-41-0 4-(bromoacetyl)toluene 
• 122-00-9 para-methylacetophenone 
• 6595-30-8 2-azido-1-(4-methylphenyl)ethan-1-one 

Downstream Products

• 603069-35-8 1-(2-cyano-phenyl)-3-(2-oxo-2-p-tolyl-ethyl)-urea 
• 1267690-21-0 N-(2-oxo-2-p-tolylethyl)nicotinamide 
• 1344674-71-0 (E)-3-(2-hydroxyphenyl)-N-(2-oxo-2-p-tolylethyl)acrylamide 
• 1344674-79-8 2-(3,4-dimethoxyphenyl)-N-(2-oxo-2-p-tolylethyl)acetamide 
• 1344674-84-5 N-(2-oxo-2-p-tolylethyl)-2-(pyridin-3-yl)acetamide 
• 1344674-85-6 (E)-N-(2-hydroxy-2-p-tolylethyl)-3-(4-hydroxyphenyl)acrylamide 
• 1344674-86-7 (E)-N-(2-hydroxy-2-p-tolylethyl)-3-(2-hydroxyphenyl)acrylamide 
• 1344674-88-9 (E)-N-(2-hydroxy-2-p-tolylethyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide 
• 1344674-89-0 (E)-3-(3,4-dichlorophenyl)-N-(2-hydroxy-2-p-tolylethyl)acrylamide 
• 1344674-90-3 4-chloro-N-(2-hydroxy-2-p-tolylethyl)-3-nitrobenzamide 
• 1344674-91-4 N-(2-hydroxy-2-p-tolylethyl)-2-(pyridin-3-yl)acetamide 
• 1344674-83-4 N-(2-oxo-2-p-tolylethyl)-3-(pyridin-3-yl)propanamide 
• 1344674-73-2 (E)-3-(4-hydroxy-3-methoxyphenyl)-N-(2-oxo-2-p-tolylethyl)acrylamide 
• 1344674-69-6 (E)-3-(4-hydroxyphenyl)-N-(2-oxo-2-p-tolylethyl)acrylamide 

Relevant academic research and scientific papers

Design, synthesis, and cytotoxic activity of novel 2H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidine derivatives

In this study, a series of novel 2H-imidazo [1, 2-c] pyrazolo [3, 4-e] pyrimidine derivatives were designed, synthesized, and evaluated for their cytotoxic activities. The in vitro cell growth inhibition assay of the target compounds indicated their selectivity in inhibiting the proliferation of blood tumor cells (K562, U937) and solid tumor cells (HCT116, HT-29). Compound 9b exhibited the highest antiproliferative activities against K562 (IC50 = 5.597 μM) and U937 (IC50 = 3.512 μM). Based on the flow cytometry assays, compound 9b caused obvious induction of cell apoptosis and cell arrest at the S phase. Furthermore, western blot analysis revealed that compound 9b upregulated the expression of Bax, downregulated the levels of Bcl-2, and further activated caspase-3 in K562 cells. Therefore, compound 9b may be a potential anticancer agent that deserves further investigation.

Pyrazole-pyrimido imidazole compound as well as preparation method and application thereof

The invention relates to a pyrazole-pyrimido imidazole compound as well as a preparation method and application thereof, and belongs to the field of medicinal chemistry and pharmacotherapeutics. The invention provides application of the compound shown in the formula I or the pharmaceutically acceptable salt thereof in preparation of drugs for treating tumor-related diseases.

Natural products as sources of new fungicides (V): Design and synthesis of acetophenone derivatives against phytopathogenic fungi in vitro and in vivo

A series of acetophenone derivatives (10a–10i, 11, 12a–12g, 13a–13g, 14a–14d and 15a–15l) were designed, synthesized and evaluated for antifungal activities in vitro and in vivo. The antifungal activities of 53 compounds were tested against several plant pathogens, and their structure–activity relationship was summarized. Compounds 10a–10f displayed better antifungal effects than two reference fungicides. Interestingly, the most potent compound 10d exhibited antifungal properties against Cytospora sp., Botrytis cinerea, Magnaporthe grisea, with IC50 values of 6.0–22.6 μg/mL, especially Cytospora sp. (IC50 = 6.0 μg/mL). In the in vivo antifungal assays, 10d displayed the significant protective efficacy of 55.3% to Botrytis cinerea and 73.1% to Cytospora sp. The findings indicated that 10d may act as a potential pesticide lead compound that merits further investigation.

Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists

A new series of morpholine derivatives has been identified as selective DA D3 receptor antagonists; their in vitro profile and pharmacokinetic data are provided.

Probing the 'bipolar' nature of the carbonic anhydrase active site: Aromatic sulfonamides containing 1,3-oxazol-5-yl moiety as picomolar inhibitors of cytosolic CA I and CA II isoforms

Abstract A series of potent inhibitors of human carbonic anhydrase (CA) isoforms I and II has been prepared via a direct, chemoselective sulfochlorination of a range of 1,3-oxazolyl benzenes and thiophenes, followed by primary sulfonamide synthesis. The latter functionality is a known zinc-binding group (ZBG) responsible for anchoring the inhibitors to the CA's zinc metal ion. The compound's periphery as well as the overall scaffold geometry was designed to enable optimal interactions with the two distinct sides of the enzyme's active site, one of which is lined with hydrophobic residues and while the other is predominantly hydrophilic. As a result, several compounds inhibiting the therapeutically important cytosolic CA I and CA II in picomolar range have been identified. These compounds are one of the most potent CA inhibitors identified to-date. Not only the remarkable (>10 000-fold), cytosolic CA I and CA II selectivity vs. the membrane-bound CA IX and CA XII isoforms, but also the pronounced CA II/I selectivity observed in some cases, allow considering this series as a set of isoform-selective chemical biology tools and promising starting points for drug candidate development.

Design, synthesis and biological activity evaluation of 2,5-diphenyl-1,3,4-oxadiazole derivatives as novel inhibitors of fructose-1,6-bisphosphatase

Fructose-1,6-bisphosphatase (FBPase), an important gluconeogenic enzyme, catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate. The effort to discover new FBPase inhibitors was carried out by high-throughput screening (HTS) of a library of 56,000 lead-like compounds, and a 2,5-diphenyl-1,3,4-oxadiazole (3a, IC50 = 15.45 μM) which bearing no phosphate group was identified as a potential FBPase inhibitor for the first time. Structure-activity-relationship (SAR) research of a series of analogues obtained by modifying the substituent groups and replacing the 1,3,4-oxadiazole with several other heterocycles disclosed the key structure and substituent groups related to the binding with FBPase.

Synthesis of novel N-(2-hydroxy-2-p-tolylethyl)-amide and N-(2-oxo-2-p-tolylethyl)-amide derivatives and their antidyslipidemic and antioxidant activity

In continuation of our drug discovery program on metabolic diseases, we identified an alkaloidal amide, that is, Aegeline (V) from the plant Aegle marmelos leaves as a dual acting agent (antihyperlipidemic and antihyperglycemic). We therefore synthesized